Trials / Recruiting
RecruitingNCT07226947
Body Composition and Exercise to Prevent Muscle Loss With GLP1 Agonist Treatment
BIA Monitoring and Exercise for the Prevention of Muscle Loss With Incretin Therapy (BICEP Study)
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- Massachusetts General Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this study is to learn if a smartwatch that measures activity level and body composition, combined with exercise reminders, can safely improve strength and muscle mass in people who recently started or are planning to start treatment with incretin therapy (liraglutide, semaglutide, tirzepatide or retatrutide), also known as glucagon-like peptide 1 receptor agonist (GLP-1 RA) medications.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Smartwatch activity and body composition monitor | Participants will be provided a smartwatch to monitor their exercise and body composition |
| BEHAVIORAL | General guidance on recommended exercise | Participants will receive general guidance on recommended exercise |
Timeline
- Start date
- 2025-11-24
- Primary completion
- 2027-06-01
- Completion
- 2027-06-01
- First posted
- 2025-11-12
- Last updated
- 2025-12-30
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT07226947. Inclusion in this directory is not an endorsement.